Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insulet Corp PODD

Healthcare Medical Devices
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also... see more

Recent & Breaking News (NDAQ:PODD)

Insulet Recognizes World Diabetes Day and Diabetes Awareness Month Throughout November

Business Wire November 1, 2022

Insulet to Announce Third Quarter 2022 Financial Results on November 3, 2022

Business Wire September 22, 2022

Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery System

Business Wire September 20, 2022

Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes

Business Wire August 22, 2022

Insulet to Present at Upcoming Investor Conferences

Business Wire August 5, 2022

Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency1)

Business Wire August 4, 2022

Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System

Business Wire August 1, 2022

Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022

Business Wire June 30, 2022

Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

Business Wire June 3, 2022

Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference

Business Wire June 2, 2022

Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia

Business Wire June 1, 2022

AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors

GlobeNewswire May 12, 2022

Insulet Announces CEO Transition

Business Wire May 5, 2022

Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year

Business Wire May 5, 2022

Insulet's 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose

Business Wire May 2, 2022

Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes

Business Wire April 27, 2022

Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022

Business Wire April 7, 2022

Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year

Business Wire February 23, 2022

Insulet Promotes Inclusivity for People with Diabetes through Nintendo® Video Game Animal Crossing(TM): New Horizons

Business Wire February 17, 2022

Insulet to Present at Upcoming Investor Conferences

Business Wire February 16, 2022